Pilot to Enhance Early Diagnosis
ADNeT, the Australian Dementia Network, unveiled a groundbreaking trial on 2 April 2026, aiming to bring Alzheimer’s blood testing to Australians. This initiative seeks to improve early diagnosis and treatment for Alzheimer’s Disease (AD). Professor Christopher Rowe, Director of ADNeT, stated, “This pilot brings forward the opportunity to one day have the combination of cognitive and blood testing available to Australians across the country.” ADNeT plans to collaborate with networks of general practitioners across three states. The initiative will combine digital cognitive tests with blood tests, specifically targeting individuals at risk of Alzheimer’s Disease. Such a large-scale study represents progress in dementia research.
Participants who exhibit signs of Alzheimer’s in the trial will be referred to Brain Health Clinics or conventional specialist memory clinics. Expert diagnosis and early treatment in these clinics are crucial in managing the disease’s progression. Dementia remains a pressing public health issue in Australia, affecting over 400,000 Australians and projected to cost the nation approximately $18.7 billion by 2025. Alzheimer’s Disease accounts for about three-quarters of dementia cases, underscoring the importance of early intervention.
ADNeT’s pre-Budget submission includes a proposed budget of $6 million over five years for the trial. This investment aims to enable earlier diagnosis and intervention, potentially saving the Australian Government billions in healthcare costs. Existing testing methods can identify signs of Alzheimer’s up to two decades before symptoms appear. The introduction of more accurate blood tests, expected later this year, could revolutionise the screening process. Professor Rowe highlighted the importance of expanding testing availability beyond metropolitan areas. He explained, “With current wait times for dementia diagnosis and treatment exceeding 12 months outside Melbourne and Sydney, there’s an urgent need for greater support for patients.”
Alzheimer’s impact is particularly severe in rural, regional, indigenous, and culturally diverse communities. These areas face longer delays in diagnosis and difficulties accessing treatment, underscoring the importance of this initiative.
Last updated: 29 June 2026, 12:35 pm
